These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 27977428

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Complement inhibition in ANCA vasculitis.
    Jayne D.
    Nephrol Ther; 2019 Nov; 15(6):409-412. PubMed ID: 31631015
    [Abstract] [Full Text] [Related]

  • 6. Kidney, hypertension and complement activation. In search of new therapeutic targets.
    Rodríguez de Córdoba S, Espinosa Hernández M.
    Nefrologia (Engl Ed); 2019 Nov; 39(2):111-114. PubMed ID: 30528890
    [No Abstract] [Full Text] [Related]

  • 7. Molecules Great and Small: The Complement System.
    Mathern DR, Heeger PS.
    Clin J Am Soc Nephrol; 2015 Sep 04; 10(9):1636-50. PubMed ID: 25568220
    [Abstract] [Full Text] [Related]

  • 8. Being an ADVOCATE for People with ANCA Vasculitis.
    Anders HJ, Nakazawa D.
    Clin J Am Soc Nephrol; 2021 Oct 04; 16(10):1581-1583. PubMed ID: 34083218
    [No Abstract] [Full Text] [Related]

  • 9. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Sengul Samanci N, Ayer M, Ergen A, Ozturk S.
    Transfus Apher Sci; 2015 Jun 04; 52(3):314-6. PubMed ID: 25634788
    [Abstract] [Full Text] [Related]

  • 10. Complement-mediated kidney diseases.
    Poppelaars F, Thurman JM.
    Mol Immunol; 2020 Dec 04; 128():175-187. PubMed ID: 33137606
    [Abstract] [Full Text] [Related]

  • 11. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies?
    Yıldız S, Demirkan F.
    Transfus Apher Sci; 2018 Feb 04; 57(1):31-34. PubMed ID: 29506907
    [Abstract] [Full Text] [Related]

  • 12. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.
    Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ.
    J Clin Invest; 2019 Mar 01; 129(3):1061-1075. PubMed ID: 30714990
    [Abstract] [Full Text] [Related]

  • 13. Anti-complement therapy for glomerular diseases.
    Bomback AS.
    Adv Chronic Kidney Dis; 2014 Mar 01; 21(2):152-8. PubMed ID: 24602464
    [Abstract] [Full Text] [Related]

  • 14. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M, Reuter S, Nozal P, López-Trascasa M, Sánchez-Corral P, Prohászka Z, Uzonyi B.
    Immunol Lett; 2014 Aug 01; 160(2):163-71. PubMed ID: 24491679
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Current and future pharmacologic complement inhibitors.
    Risitano AM.
    Hematol Oncol Clin North Am; 2015 Jun 01; 29(3):561-82. PubMed ID: 26043392
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.